CLINUVEL Pharmaceuticals Reports Lapse of Over 124,000 Performance Rights

CLINUVEL Pharmaceuticals Limited announced the cessation of 124,153 performance rights on July 24, 2026. This occurred because the conditions for these conditional rights to securities were not met or could no longer be satisfied, as detailed in a regulatory filing with the Australian Securities Exchange. This is a routine update on employee or executive compensation-related securities.